by Meriem Bouslouk-Marx | Sep 7, 2023 | News
After Boehringer Ingelheim’s announcement to withdraw a medicine for the treatment of a rare skin disease from the German market on 29 August 2023, a heated debate has erupted on the benefit assessment of new therapies in Germany. Boehringer Ingelheim said the health...
by Meriem Bouslouk-Marx | Apr 17, 2023 | News
Do you know IMAS? If you are a professional in Market Access who believes that your education and training are crucial for patient access to relevant therapies, then you should! IMAS stands for International Market Access Society. It derives from MAS, the Market...
by Meriem Bouslouk-Marx | Feb 28, 2023 | News
I remember very well the day I asked the G-BA for permission to speak about the specific German benefit assessment of orphan drugs. Although I used to represent the G-BA and AMNOG internationally, I did not dare to give a talk solely on orphan drugs. Why? Because I...
by Meriem Bouslouk-Marx | Feb 14, 2023 | News
The G-BA took the opportunity to announce its work programme for 2023 at a press conference on 14 February 2023. The impartial G-BA Chair professor Josef Hecken highlighted in his introduction speech that the G-BA had made over 1,000 benefit assessment decisions since...
by Meriem Bouslouk-Marx | Feb 10, 2023 | News
While the last day of February is known as the Rare Disease Day, the first days of February 2023 mark the start of changes for rare diseases at the G-BA in Germany. On 2 February 2023, the G-BA decided on the provisory suspension of two ongoing benefit assessments for...